A novel recombinant human anti-PD-1 monoclonal antibody GLS-010 in patients with advanced cancer: Result of a phase Ia clinical trial

被引：0
|
作者：
Shen, L. [1 ]
Gong, J. [1 ]
Xu, Y. [1 ]
Zhang, X. [1 ]
Peng, Z. [1 ]
Qi, C. [1 ]
Li, G. [2 ]
Meng, H. [2 ]
Liu, Z. [2 ]
Wang, H. [2 ]
Chen, C. [3 ]
Li, J. [3 ]
Zheng, Y. [3 ]
Lee, J. [4 ]
Zhang, Y. [4 ]
Zhang, Q. [4 ]
机构：
[1] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
[2] Guangzhou Gloria Biosci Co Ltd, Gloria Biosci, Beijing, Peoples R China
[3] WuXi Biol Shanghai Co Ltd, WuXi Biol, Shanghai, Peoples R China
[4] Wuxi Clin Dev Serv Shanghai Co Ltd, Wuxi Clin, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
65P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies
    Song, Xuyang
    Khan, Anis A.
    Zhou, Diansong
    Elgeioushi, Nairouz
    Walcott, Farzana
    Ren, Song
    Gibbs, Megan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 373 - 382
  • [22] Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies
    Xuyang Song
    Anis A. Khan
    Diansong Zhou
    Nairouz Elgeioushi
    Farzana Walcott
    Song Ren
    Megan Gibbs
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 373 - 382
  • [23] Anti-PD-1 antibody MDX-1106 enters Phase Ib clinical trial for cancer therapy
    不详
    IMMUNOTHERAPY, 2009, 1 (01) : 11 - 11
  • [24] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [25] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [26] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [27] Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS']JS001) in Chinese patients with refractory solid tumors
    Wang, F-H.
    Ren, C.
    Zhang, Y.
    Yao, S.
    Feng, H.
    Wu, H.
    Song, H-F.
    Zhang, R.
    Wei, X-L.
    Xia, X-J.
    Zhao, Q.
    Yun, J-P.
    Zou, B-Y.
    Qiu, M.
    Wang, Z-Q.
    Li, Y-H.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [28] A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
    Naing, A.
    Goel, S.
    Curti, B.
    Weise, A.
    Eder, J. P.
    Marshall, S.
    Morehouse, C.
    Li, X.
    Karakunnel, J. J.
    Infante, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced NSCLC and MSI-H endometrial cancer
    Moreno, Victor
    Barretina-Ginesta, Maria-Pilar
    Guo, Wei
    Lu, Sharon
    Jenkins, David
    McEachern, Kristen
    Reichert, Vienna
    Dunlap, Steven
    Im, Ellie
    Gilbert, Lucy
    Oaknin, Ana
    Leath, Charles, III
    Subramanian, Janakiraman
    CANCER RESEARCH, 2018, 78 (13)
  • [30] The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
    Oliver Coen
    Pippa Corrie
    Helen Marshall
    Ruth Plummer
    Christian Ottensmeier
    Jane Hook
    Sue Bell
    Gurdeep S. Sagoo
    David Meads
    Janine Bestall
    Galina Velikova
    Ferdia A. Gallagher
    Alexandra Smith
    Helen Howard
    Ellen Mason
    Eszter Katona
    Shobha Silva
    Michelle Collinson
    Simon Rodwell
    Sarah Danson
    BMC Cancer, 21
12345